RNA in the 13F filings
Atrium Therapeutics Inc · CUSIP 04965N104
New listing in Q1 2026· first held by a tracked manager this quarter, so its new positions are allocations rather than a turn towards it
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 22
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 0 listed it in both
- Shares listed
- 3,614,204
- combined, among listed positions
- Reported value
- $48m
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 22 buyers (opened or added shares) and 0 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +3,614,204.
Managers listing RNA in Q1 2026
22 of 22 holders
Largest increases and reductions, by shares
Increases
- T. Rowe Price Associates Incnew position · 1,553,210 shares now+1,553,210
- Farallon Capital Management LLCnew position · 349,360 shares now+349,360
- Balyasny Asset Management LLCnew position · 235,115 shares now+235,115
- Squarepoint Ops LLCnew position · 231,466 shares now+231,466
- Millennium Management LLCnew position · 190,859 shares now+190,859
Reductions
No reduction among listed positions.
New positions and exits
New (22)
- T. Rowe Price Associates Inc$21m
- Farallon Capital Management LLC$4.7m
- Balyasny Asset Management LLC$3.1m
- Squarepoint Ops LLC$3.1m
- Millennium Management LLC$2.6m
- Two Sigma Investments LP$2.4m
- Schonfeld Strategic Advisors LLC$2.2m
- Janus Henderson Group Ltd$1.9m
- Citadel Advisors LLC$1.5m
- ExodusPoint Capital Management LP$1.0m
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
One quarter on file so far, so there is nothing to draw yet.
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
RNA and LLY →RNA and TMO →RNA and JNJ →Choose a stock to compare with RNA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own RNA, latest filings →Back to the 13F Explorer →